Ftse Mib
33.843,83
1,08%
DAX
20.016,75
0,55%
S&P 500
6.040,12
-0,12%
NASDAQ
19.404,85
0,00%
Bitcoin
95.136,23
-0,76%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Amarin Corp PLC (AMRN) Amarin Corp PLC (AMRN) Notizie

Amarin Corp PLC

AMRN
0,5199
-0,0058 (-1,10%)
Ultimo aggiornamento: 18:16:19
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
22/11/202422:49EDGAR2Form 8-K - Current report
11/11/202414:00GLOBEInvestigators to Present New REDUCE-IT Subanalysis of..
31/10/202421:42EDGAR2Form 3 - Initial statement of beneficial ownership of..
30/10/202421:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
30/10/202421:10EDGAR2Form 8-K - Current report
30/10/202421:05GLOBEAmarin Reports Third Quarter 2024 Financial Results and..
01/10/202414:00GLOBEAmarin Announces Two Upcoming Investor Events
09/9/202413:30GLOBEResearch Highlighting the Clinical Impact of..
22/8/202414:30GLOBELatest Research Highlighting VASCEPA®/VAZKEPA® (icosapent..
05/8/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/8/202422:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/8/202422:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/7/202413:05EDGAR2Form 8-K - Current report
31/7/202413:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
31/7/202413:00GLOBEAmarin Reports Second Quarter 2024 Financial Results and..
29/7/202423:30EDGAR2Form 8-K - Current report
17/7/202422:15GLOBEAmarin Receives National Reimbursement for VAZKEPA®..
17/7/202414:00GLOBEAmarin to Report Second Quarter 2024 Financial Results and..
08/7/202413:30GLOBEAmarin Partner EddingPharm Receives Regulatory Approval for..
04/6/202413:30EDGAR2Form 8-K - Current report
04/6/202413:30GLOBEAmarin Board of Directors Announces CEO Transition
28/5/202414:15GLOBE Amarin Receives National Reimbursement for VAZKEPA®..
06/5/202414:00GLOBEAmarin to Present at H.C. Wainwright 2nd Annual BioConnect..
01/5/202413:00GLOBE Amarin Reports First Quarter 2024 Business Update and..
24/4/202420:00GLOBEAmarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA..
22/4/202414:00GLOBEAmarin Announces Results of Annual General Meeting of..
15/4/202414:00GLOBEAmarin to Report First Quarter 2024 Financial Results and..
08/4/202414:00GLOBEAmarin Highlights Key Data Providing Mechanistic Insights..
08/4/202412:30PRNCANew REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl)..
06/4/202421:30GLOBENew REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent..
03/4/202414:00GLOBEAmarin Provides Update on VAZKEPA® (Icosapent Ethyl)..
25/3/202413:00GLOBEResearch Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent..
04/3/202414:00EDGAR2Form DEF 14A - Other definitive proxy statements
29/2/202413:06EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29/2/202413:05EDGAR2Form 8-K - Current report
29/2/202413:00GLOBEAmarin Reports Fourth Quarter and Full Year 2023 Financial..
15/2/202414:00GLOBEAmarin to Report Fourth Quarter and Full Year 2023 Financial..
12/2/202414:00EDGAR2Form PRE 14A - Other preliminary proxy statements
09/2/202422:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/1/202413:00EDGAR2Form 8-K - Current report
24/1/202422:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/1/202413:30GLOBEAmarin Chairman & CEO Issue Letter to Shareholders
12/1/202423:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/1/202423:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/1/202423:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 0,5153 Min: 0,5067 Max: 0,527
Chiusura: 0,5257

La tua Cronologia

NASDAQ
AMRN
Amarin
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network